Loading patent…
AssigneesThe University of Tokyo, Kyushu University, National University Corporation, NH Foods Ltd., National Center of Neurology and Psychiatry
InventorsTatsuhiro Hisatsune, Mamoru Totsuka, Hideo Satsu, Jun Kaneko, Yoshinori Katakura, Mikako Sato, Takashi Matsumoto, Fumiki Morimatsu, Etsuko Imabayashi, Hiroshi Matsuda
Estimating the term…
An anti-aging agent derived from a natural product is provided. The agent uses at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof as an active ingredient. The present invention also provides an agent for improving a neuropsychologic function, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof as an active ingredient. The present invention also provides an agent for changing expression of a transporter such as SLC23A2, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof, and an agent for controlling blood concentration of a cytokine such as IP-10, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof, as well as an expression analysis method for detecting improvement or degradation of a neuropsychologic function, and a kit for detecting improvement or degradation of a neuropsychologic function.
An agent for improving a neuropsychologic function, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof.
An anti-aging agent based on improvement of a neuropsychologic function, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof.
An agent for changing expression of at least one kind of gene selected from the group consisting of:
An agent for controlling blood concentration of at least one kind of cytokine selected from the group consisting of IP-10 (CXCL10), IL-2, IL-5, IL-7, IL-8 (CXCL8), IL-13, G-CSF, and MCP-1 (CCL2), which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof.
A nutritional composition containing 200 mg or more as a daily dose of at least one kind of imidazole dipeptide derived from animal meat.
An agent for a treatment of diabetes and/or Alzheimer disease, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof.
A dieting method comprising making a subject for whom improvement of a neuropsychologic function is desirable ingest a nutritional composition containing at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof.
A method for determining a neuropsychologic function of a subject, which is based on a carnosine decomposition enzyme (CNDP1) activity of the subject.
A method for detecting improvement or degradation of a neuropsychologic function, which is based on analysis of expression of at least one kind of gene selected from the group consisting of:
A kit for detecting improvement or degradation of a neuropsychologic function which comprises
A pharmaceutical composition for a treatment of aging of cerebral function and/or dementia, which contains a compound represented by the formula I or II:
Dependencies are inferred from the claim text.